Robert Freedman
Concepts (531)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 72 | 2020 | 464 | 8.650 |
Why?
| | Choline | 12 | 2024 | 138 | 4.580 |
Why?
| | Evoked Potentials, Auditory | 39 | 2024 | 181 | 3.560 |
Why?
| | Receptors, Nicotinic | 37 | 2013 | 327 | 3.370 |
Why?
| | Nicotinic Agonists | 15 | 2016 | 135 | 3.230 |
Why?
| | Brain | 35 | 2021 | 2969 | 2.390 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 24 | 2016 | 94 | 2.260 |
Why?
| | Hippocampus | 31 | 2013 | 973 | 1.980 |
Why?
| | Psychotic Disorders | 9 | 2021 | 192 | 1.850 |
Why?
| | Prenatal Exposure Delayed Effects | 8 | 2021 | 655 | 1.810 |
Why?
| | Hot Flashes | 7 | 2014 | 92 | 1.800 |
Why?
| | Neural Inhibition | 17 | 2013 | 178 | 1.710 |
Why?
| | Sensory Gating | 8 | 2020 | 44 | 1.710 |
Why?
| | Psychiatry | 5 | 2018 | 195 | 1.700 |
Why?
| | Benzylidene Compounds | 8 | 2013 | 20 | 1.650 |
Why?
| | Schizophrenic Psychology | 19 | 2015 | 99 | 1.640 |
Why?
| | Periodicals as Topic | 5 | 2018 | 209 | 1.590 |
Why?
| | Folic Acid | 4 | 2024 | 198 | 1.470 |
Why?
| | Pregnancy Complications, Infectious | 4 | 2021 | 440 | 1.410 |
Why?
| | Nicotine | 17 | 2013 | 331 | 1.400 |
Why?
| | Fetal Development | 9 | 2024 | 298 | 1.400 |
Why?
| | Pyridines | 8 | 2013 | 609 | 1.200 |
Why?
| | Antidepressive Agents | 3 | 2023 | 242 | 1.180 |
Why?
| | Chromosomes, Human, Pair 15 | 16 | 2015 | 50 | 1.160 |
Why?
| | Attention | 18 | 2020 | 463 | 1.150 |
Why?
| | Ketamine | 2 | 2023 | 137 | 1.120 |
Why?
| | Gestational Age | 6 | 2024 | 990 | 1.090 |
Why?
| | Pursuit, Smooth | 9 | 2007 | 19 | 1.080 |
Why?
| | Maternal Exposure | 2 | 2019 | 189 | 1.020 |
Why?
| | Pregnancy | 18 | 2024 | 7216 | 0.920 |
Why?
| | Acoustic Stimulation | 20 | 2020 | 333 | 0.900 |
Why?
| | Menopause | 4 | 2014 | 326 | 0.880 |
Why?
| | Mental Disorders | 5 | 2021 | 1171 | 0.840 |
Why?
| | Evoked Potentials | 7 | 2020 | 131 | 0.820 |
Why?
| | Child Behavior | 2 | 2016 | 236 | 0.790 |
Why?
| | Child Development | 5 | 2024 | 483 | 0.780 |
Why?
| | Electroconvulsive Therapy | 1 | 2023 | 16 | 0.780 |
Why?
| | Dietary Supplements | 5 | 2021 | 584 | 0.770 |
Why?
| | Humans | 125 | 2024 | 145783 | 0.750 |
Why?
| | Auditory Perception | 8 | 2004 | 115 | 0.740 |
Why?
| | Prenatal Care | 4 | 2021 | 309 | 0.740 |
Why?
| | Body Temperature Regulation | 4 | 2013 | 105 | 0.720 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 118 | 0.700 |
Why?
| | Reflex, Startle | 3 | 2014 | 75 | 0.700 |
Why?
| | Phosphatidylcholines | 3 | 2018 | 131 | 0.690 |
Why?
| | Antipsychotic Agents | 8 | 2008 | 211 | 0.680 |
Why?
| | Micronutrients | 2 | 2021 | 102 | 0.670 |
Why?
| | Infant Behavior | 2 | 2020 | 28 | 0.660 |
Why?
| | Infant, Newborn | 10 | 2024 | 6465 | 0.640 |
Why?
| | Female | 74 | 2024 | 79045 | 0.640 |
Why?
| | Smoking | 14 | 2013 | 1477 | 0.630 |
Why?
| | Brain Mapping | 6 | 2013 | 542 | 0.630 |
Why?
| | Adult | 55 | 2024 | 40881 | 0.600 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 2 | 2018 | 56 | 0.590 |
Why?
| | Prefrontal Cortex | 3 | 2016 | 336 | 0.590 |
Why?
| | Neurons | 10 | 2019 | 1652 | 0.590 |
Why?
| | Editorial Policies | 2 | 2018 | 45 | 0.570 |
Why?
| | Hallucinogens | 1 | 2021 | 111 | 0.560 |
Why?
| | Magnetic Resonance Imaging | 13 | 2013 | 3916 | 0.560 |
Why?
| | Endophenotypes | 2 | 2015 | 23 | 0.560 |
Why?
| | Perceptual Disorders | 3 | 2005 | 24 | 0.560 |
Why?
| | Saccades | 7 | 2007 | 46 | 0.550 |
Why?
| | Electroencephalography | 11 | 2020 | 563 | 0.550 |
Why?
| | Hydrocortisone | 1 | 2020 | 298 | 0.540 |
Why?
| | Male | 79 | 2024 | 73010 | 0.540 |
Why?
| | C-Reactive Protein | 4 | 2022 | 423 | 0.540 |
Why?
| | Nootropic Agents | 2 | 2020 | 30 | 0.540 |
Why?
| | Betacoronavirus | 1 | 2020 | 289 | 0.500 |
Why?
| | Premature Birth | 1 | 2021 | 390 | 0.500 |
Why?
| | Problem Behavior | 1 | 2018 | 101 | 0.490 |
Why?
| | Interneurons | 6 | 2001 | 125 | 0.470 |
Why?
| | Primary Prevention | 1 | 2018 | 222 | 0.470 |
Why?
| | Arousal | 6 | 1993 | 157 | 0.470 |
Why?
| | Image Processing, Computer-Assisted | 6 | 2013 | 783 | 0.470 |
Why?
| | Depression | 2 | 2023 | 1559 | 0.470 |
Why?
| | Marijuana Smoking | 1 | 2019 | 249 | 0.460 |
Why?
| | Psychological Trauma | 1 | 2016 | 57 | 0.460 |
Why?
| | Validation Studies as Topic | 1 | 2015 | 23 | 0.450 |
Why?
| | Afferent Pathways | 3 | 2013 | 46 | 0.440 |
Why?
| | Cognition Disorders | 3 | 2010 | 544 | 0.440 |
Why?
| | Bungarotoxins | 10 | 2008 | 45 | 0.430 |
Why?
| | Amygdala | 1 | 2016 | 200 | 0.420 |
Why?
| | Genotype | 9 | 2015 | 1857 | 0.420 |
Why?
| | Sleep | 4 | 2014 | 889 | 0.420 |
Why?
| | Aggression | 1 | 2016 | 180 | 0.410 |
Why?
| | Sleep, REM | 3 | 2006 | 44 | 0.410 |
Why?
| | Reaction Time | 7 | 2020 | 434 | 0.400 |
Why?
| | Cannabis | 1 | 2021 | 510 | 0.400 |
Why?
| | Teaching | 1 | 2016 | 237 | 0.390 |
Why?
| | Eye Movements | 4 | 2013 | 94 | 0.380 |
Why?
| | Phosphorylcholine | 1 | 2013 | 19 | 0.380 |
Why?
| | Gyrus Cinguli | 4 | 2006 | 97 | 0.380 |
Why?
| | Sleep Apnea Syndromes | 1 | 2014 | 98 | 0.380 |
Why?
| | Neural Pathways | 4 | 2010 | 317 | 0.370 |
Why?
| | Mothers | 5 | 2021 | 766 | 0.370 |
Why?
| | Genetic Linkage | 10 | 2012 | 273 | 0.370 |
Why?
| | Double-Blind Method | 6 | 2016 | 2064 | 0.350 |
Why?
| | Neuropsychological Tests | 6 | 2016 | 1137 | 0.350 |
Why?
| | Clozapine | 4 | 2004 | 20 | 0.340 |
Why?
| | Ocular Motility Disorders | 2 | 2004 | 42 | 0.340 |
Why?
| | Cerebral Cortex | 6 | 2006 | 474 | 0.330 |
Why?
| | Autism Spectrum Disorder | 1 | 2016 | 423 | 0.330 |
Why?
| | Emotions | 2 | 2016 | 577 | 0.330 |
Why?
| | Nicotinic Antagonists | 6 | 2008 | 36 | 0.310 |
Why?
| | 5-Hydroxytryptophan | 1 | 2009 | 19 | 0.310 |
Why?
| | Middle Aged | 30 | 2016 | 36309 | 0.300 |
Why?
| | Dopamine | 7 | 2009 | 295 | 0.300 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 46 | 0.300 |
Why?
| | Cognition | 3 | 2016 | 1271 | 0.300 |
Why?
| | Schizotypal Personality Disorder | 2 | 2002 | 11 | 0.300 |
Why?
| | Peer Review, Research | 1 | 2009 | 36 | 0.300 |
Why?
| | Sensation Disorders | 2 | 2007 | 40 | 0.300 |
Why?
| | Fetus | 4 | 2021 | 804 | 0.290 |
Why?
| | Cocaine-Related Disorders | 2 | 2001 | 133 | 0.290 |
Why?
| | Infant | 9 | 2021 | 10091 | 0.280 |
Why?
| | Biomedical Research | 1 | 2015 | 719 | 0.280 |
Why?
| | Thalamus | 2 | 2007 | 129 | 0.280 |
Why?
| | Mice, Inbred DBA | 4 | 2008 | 182 | 0.280 |
Why?
| | Nitric Oxide Synthase | 2 | 2000 | 234 | 0.280 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2007 | 185 | 0.270 |
Why?
| | Writing | 1 | 2009 | 101 | 0.270 |
Why?
| | Body Temperature | 2 | 2007 | 227 | 0.270 |
Why?
| | Sensory Aids | 1 | 2007 | 4 | 0.260 |
Why?
| | Child, Preschool | 6 | 2024 | 11868 | 0.260 |
Why?
| | Miniaturization | 1 | 2007 | 22 | 0.260 |
Why?
| | Neurons, Afferent | 2 | 1999 | 102 | 0.260 |
Why?
| | Auditory Perceptual Disorders | 3 | 2008 | 8 | 0.250 |
Why?
| | Equipment and Supplies | 1 | 2007 | 37 | 0.250 |
Why?
| | Neostriatum | 1 | 2007 | 37 | 0.250 |
Why?
| | Synaptic Transmission | 6 | 2024 | 292 | 0.250 |
Why?
| | Humidity | 1 | 2007 | 49 | 0.250 |
Why?
| | Learning | 2 | 2009 | 444 | 0.250 |
Why?
| | Phenotype | 7 | 2018 | 3170 | 0.240 |
Why?
| | Contingent Negative Variation | 2 | 2005 | 9 | 0.240 |
Why?
| | Genetic Markers | 7 | 2012 | 338 | 0.240 |
Why?
| | Child of Impaired Parents | 2 | 1996 | 38 | 0.240 |
Why?
| | Pedigree | 8 | 2009 | 515 | 0.240 |
Why?
| | Acetylcholine | 3 | 2002 | 209 | 0.240 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2005 | 14 | 0.230 |
Why?
| | N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2005 | 11 | 0.230 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.230 |
Why?
| | Biomarkers | 3 | 2015 | 4302 | 0.230 |
Why?
| | Genetic Predisposition to Disease | 6 | 2013 | 2399 | 0.230 |
Why?
| | Animals | 34 | 2021 | 38101 | 0.220 |
Why?
| | Internship and Residency | 1 | 2016 | 1269 | 0.220 |
Why?
| | Sensation | 3 | 1991 | 55 | 0.220 |
Why?
| | Galvanic Skin Response | 3 | 2013 | 26 | 0.220 |
Why?
| | Receptors, Cholinergic | 5 | 2009 | 41 | 0.220 |
Why?
| | Child | 9 | 2021 | 22740 | 0.220 |
Why?
| | Reference Values | 8 | 2002 | 798 | 0.220 |
Why?
| | Time Perception | 1 | 2005 | 31 | 0.210 |
Why?
| | Mice, Inbred C3H | 2 | 2001 | 254 | 0.210 |
Why?
| | Sleep Deprivation | 1 | 2006 | 206 | 0.200 |
Why?
| | Cross-Over Studies | 3 | 2016 | 610 | 0.200 |
Why?
| | Norepinephrine | 5 | 1992 | 201 | 0.190 |
Why?
| | Young Adult | 5 | 2022 | 14254 | 0.190 |
Why?
| | Pyramidal Cells | 3 | 2003 | 80 | 0.190 |
Why?
| | Bipolar Disorder | 4 | 2007 | 291 | 0.190 |
Why?
| | Echo-Planar Imaging | 1 | 2002 | 24 | 0.190 |
Why?
| | Homovanillic Acid | 5 | 1990 | 10 | 0.190 |
Why?
| | Promoter Regions, Genetic | 4 | 2003 | 1247 | 0.180 |
Why?
| | Publishing | 2 | 2016 | 114 | 0.170 |
Why?
| | Wakefulness | 2 | 2001 | 170 | 0.170 |
Why?
| | Linkage Disequilibrium | 2 | 2009 | 255 | 0.170 |
Why?
| | Rats | 16 | 2002 | 5585 | 0.170 |
Why?
| | Hearing Disorders | 1 | 2001 | 10 | 0.170 |
Why?
| | Social Problems | 1 | 2021 | 12 | 0.170 |
Why?
| | Phencyclidine | 3 | 1992 | 4 | 0.160 |
Why?
| | Vitamin A | 1 | 2021 | 62 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2010 | 2028 | 0.160 |
Why?
| | Reward | 1 | 2023 | 248 | 0.160 |
Why?
| | Vitamin D | 2 | 2021 | 404 | 0.160 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2021 | 143 | 0.160 |
Why?
| | Frontal Lobe | 3 | 2006 | 160 | 0.160 |
Why?
| | Oxygen | 3 | 2013 | 981 | 0.160 |
Why?
| | Sweating | 2 | 2013 | 43 | 0.160 |
Why?
| | Gene Expression Regulation | 3 | 2015 | 2601 | 0.160 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2004 | 430 | 0.150 |
Why?
| | Object Attachment | 1 | 2020 | 48 | 0.150 |
Why?
| | Chromosome Mapping | 4 | 2009 | 507 | 0.150 |
Why?
| | Vitamins | 1 | 2021 | 184 | 0.150 |
Why?
| | Analysis of Variance | 5 | 2008 | 1300 | 0.150 |
Why?
| | Schizophrenia, Childhood | 1 | 1999 | 3 | 0.150 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2005 | 533 | 0.150 |
Why?
| | Bombesin | 1 | 1999 | 10 | 0.150 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 164 | 0.140 |
Why?
| | Genetic Variation | 3 | 2003 | 977 | 0.140 |
Why?
| | Rats, Sprague-Dawley | 8 | 2002 | 2525 | 0.140 |
Why?
| | Alleles | 5 | 2009 | 896 | 0.140 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 199 | 0.140 |
Why?
| | Maternal Age | 1 | 2019 | 128 | 0.140 |
Why?
| | Logistic Models | 2 | 2022 | 2139 | 0.140 |
Why?
| | Disease Models, Animal | 8 | 2009 | 4568 | 0.140 |
Why?
| | Catecholamines | 3 | 2002 | 88 | 0.140 |
Why?
| | Nutritional Status | 1 | 2021 | 353 | 0.140 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2013 | 47 | 0.140 |
Why?
| | DNA Mutational Analysis | 3 | 2013 | 410 | 0.140 |
Why?
| | RNA, Messenger | 7 | 2006 | 2805 | 0.140 |
Why?
| | Psychomotor Performance | 4 | 2005 | 324 | 0.140 |
Why?
| | Stem Cells | 1 | 2002 | 630 | 0.140 |
Why?
| | Risk Factors | 10 | 2021 | 10919 | 0.130 |
Why?
| | Irritable Mood | 1 | 2018 | 50 | 0.130 |
Why?
| | History, 21st Century | 1 | 2018 | 222 | 0.130 |
Why?
| | Dentate Gyrus | 1 | 1997 | 41 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2012 | 2181 | 0.130 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 910 | 0.130 |
Why?
| | Postmortem Changes | 3 | 2006 | 15 | 0.130 |
Why?
| | Adolescent | 12 | 2017 | 22577 | 0.130 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2017 | 31 | 0.130 |
Why?
| | Family | 4 | 2015 | 685 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 210 | 0.120 |
Why?
| | Gene Expression | 5 | 2006 | 1478 | 0.120 |
Why?
| | Neurocognitive Disorders | 1 | 1996 | 33 | 0.120 |
Why?
| | Data Interpretation, Statistical | 1 | 1998 | 368 | 0.120 |
Why?
| | Electrophysiology | 6 | 2003 | 218 | 0.120 |
Why?
| | Chewing Gum | 2 | 2007 | 8 | 0.120 |
Why?
| | Skin Temperature | 2 | 2006 | 36 | 0.120 |
Why?
| | Prepulse Inhibition | 1 | 2015 | 12 | 0.110 |
Why?
| | Nitric Oxide | 1 | 2000 | 892 | 0.110 |
Why?
| | Vanilmandelic Acid | 4 | 1990 | 4 | 0.110 |
Why?
| | Methoxyhydroxyphenylglycol | 4 | 1990 | 13 | 0.110 |
Why?
| | Benzodiazepines | 2 | 2008 | 168 | 0.110 |
Why?
| | Treatment Outcome | 2 | 2023 | 11794 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2002 | 2050 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1711 | 0.110 |
Why?
| | Twins | 1 | 1996 | 152 | 0.110 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2013 | 152 | 0.110 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 396 | 0.110 |
Why?
| | Electromyography | 3 | 2005 | 419 | 0.100 |
Why?
| | Postmenopause | 2 | 2007 | 394 | 0.100 |
Why?
| | Snoring | 1 | 2014 | 19 | 0.100 |
Why?
| | Cerebrovascular Circulation | 2 | 2007 | 290 | 0.100 |
Why?
| | Synapsins | 1 | 1993 | 13 | 0.100 |
Why?
| | Synaptophysin | 1 | 1993 | 15 | 0.100 |
Why?
| | Hot Temperature | 2 | 2007 | 396 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 33 | 0.100 |
Why?
| | Polymorphism, Genetic | 4 | 2009 | 615 | 0.100 |
Why?
| | Corpus Striatum | 2 | 1992 | 179 | 0.100 |
Why?
| | Cerebellum | 5 | 2002 | 224 | 0.100 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2003 | 26 | 0.100 |
Why?
| | Sleep Stages | 1 | 1993 | 76 | 0.100 |
Why?
| | Brain Tissue Transplantation | 1 | 1992 | 19 | 0.090 |
Why?
| | Fetal Tissue Transplantation | 1 | 1992 | 33 | 0.090 |
Why?
| | Mesencephalon | 1 | 1992 | 65 | 0.090 |
Why?
| | Zinc | 1 | 1995 | 307 | 0.090 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 143 | 0.090 |
Why?
| | Parasympathetic Nervous System | 1 | 1992 | 26 | 0.090 |
Why?
| | Auditory Pathways | 1 | 1992 | 53 | 0.090 |
Why?
| | Genomics | 1 | 2018 | 830 | 0.090 |
Why?
| | Perinatal Care | 1 | 2013 | 59 | 0.090 |
Why?
| | Heart Rate | 2 | 2007 | 856 | 0.090 |
Why?
| | Functional Laterality | 1 | 2013 | 240 | 0.090 |
Why?
| | Immunity | 1 | 2013 | 140 | 0.090 |
Why?
| | Iodine Radioisotopes | 4 | 2001 | 138 | 0.090 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2003 | 194 | 0.090 |
Why?
| | Gene Frequency | 2 | 2005 | 489 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2015 | 2933 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1151 | 0.090 |
Why?
| | Inflammation | 2 | 2021 | 2884 | 0.090 |
Why?
| | Alcoholism | 3 | 2003 | 826 | 0.090 |
Why?
| | Gene Duplication | 3 | 2015 | 66 | 0.090 |
Why?
| | Pregnancy Complications | 2 | 2019 | 603 | 0.090 |
Why?
| | United States | 3 | 2018 | 16126 | 0.080 |
Why?
| | Blood Pressure | 3 | 2007 | 1782 | 0.080 |
Why?
| | Circadian Rhythm | 2 | 2013 | 513 | 0.080 |
Why?
| | Memory | 1 | 2013 | 297 | 0.080 |
Why?
| | Administration, Oral | 2 | 2005 | 867 | 0.080 |
Why?
| | Event-Related Potentials, P300 | 2 | 2003 | 17 | 0.080 |
Why?
| | Time Factors | 4 | 2005 | 7134 | 0.080 |
Why?
| | Aged | 10 | 2015 | 26217 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2012 | 371 | 0.080 |
Why?
| | Photic Stimulation | 2 | 2002 | 264 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2012 | 3634 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2014 | 303 | 0.070 |
Why?
| | Mice | 8 | 2009 | 18355 | 0.070 |
Why?
| | Electrooculography | 2 | 2001 | 13 | 0.070 |
Why?
| | Alprazolam | 1 | 1988 | 6 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2009 | 191 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2012 | 371 | 0.070 |
Why?
| | Education, Distance | 1 | 2009 | 59 | 0.070 |
Why?
| | Lorazepam | 1 | 1988 | 26 | 0.070 |
Why?
| | Diazepam | 1 | 1988 | 33 | 0.070 |
Why?
| | Field Dependence-Independence | 1 | 2008 | 6 | 0.070 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2009 | 92 | 0.070 |
Why?
| | Rats, Inbred Strains | 6 | 1992 | 321 | 0.070 |
Why?
| | Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.070 |
Why?
| | Glycols | 1 | 1988 | 5 | 0.070 |
Why?
| | Risk | 2 | 2002 | 923 | 0.070 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 1988 | 39 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5428 | 0.070 |
Why?
| | Dihydro-beta-Erythroidine | 2 | 2008 | 6 | 0.070 |
Why?
| | Genes | 2 | 1998 | 228 | 0.060 |
Why?
| | Nerve Net | 2 | 2002 | 286 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5925 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1296 | 0.060 |
Why?
| | Diseases in Twins | 1 | 1988 | 116 | 0.060 |
Why?
| | Models, Neurological | 2 | 2000 | 250 | 0.060 |
Why?
| | Auditory Cortex | 1 | 2007 | 46 | 0.060 |
Why?
| | Depressive Disorder | 1 | 1990 | 374 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2012 | 157 | 0.060 |
Why?
| | Prospective Studies | 1 | 2019 | 8078 | 0.060 |
Why?
| | Monitoring, Ambulatory | 1 | 2007 | 89 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1752 | 0.060 |
Why?
| | Parkinson Disease | 1 | 1992 | 601 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 782 | 0.060 |
Why?
| | Drug Interactions | 2 | 2008 | 405 | 0.060 |
Why?
| | Telemetry | 1 | 2005 | 40 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2007 | 2000 | 0.060 |
Why?
| | Genome | 2 | 2006 | 305 | 0.060 |
Why?
| | Memory, Short-Term | 1 | 2008 | 269 | 0.060 |
Why?
| | Sequence Analysis, DNA | 3 | 2003 | 778 | 0.060 |
Why?
| | Menstrual Cycle | 1 | 2006 | 145 | 0.050 |
Why?
| | Quetiapine Fumarate | 1 | 2004 | 26 | 0.050 |
Why?
| | Dibenzothiazepines | 1 | 2004 | 18 | 0.050 |
Why?
| | Statistics as Topic | 1 | 2005 | 283 | 0.050 |
Why?
| | Cold Temperature | 1 | 2006 | 206 | 0.050 |
Why?
| | Parietal Lobe | 1 | 2005 | 61 | 0.050 |
Why?
| | Risperidone | 1 | 2004 | 30 | 0.050 |
Why?
| | Internet | 1 | 2009 | 693 | 0.050 |
Why?
| | Visual Pathways | 1 | 2005 | 61 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 2123 | 0.050 |
Why?
| | Verbal Behavior | 1 | 2004 | 42 | 0.050 |
Why?
| | Area Under Curve | 1 | 2005 | 332 | 0.050 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 2003 | 5 | 0.050 |
Why?
| | Dopamine Antagonists | 1 | 2003 | 26 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2005 | 251 | 0.050 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 229 | 0.050 |
Why?
| | Visual Fields | 1 | 2004 | 116 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 318 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 562 | 0.050 |
Why?
| | Mental Recall | 2 | 1996 | 223 | 0.050 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 232 | 0.050 |
Why?
| | Action Potentials | 6 | 1993 | 502 | 0.050 |
Why?
| | Haloperidol | 1 | 2002 | 32 | 0.050 |
Why?
| | Head | 1 | 2004 | 123 | 0.050 |
Why?
| | Age of Onset | 2 | 2007 | 557 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2005 | 719 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 592 | 0.050 |
Why?
| | Purkinje Cells | 5 | 1988 | 65 | 0.050 |
Why?
| | Chromosome Disorders | 2 | 1999 | 47 | 0.040 |
Why?
| | Radioligand Assay | 1 | 2001 | 36 | 0.040 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2001 | 15 | 0.040 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2001 | 17 | 0.040 |
Why?
| | Lod Score | 1 | 2001 | 62 | 0.040 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2001 | 60 | 0.040 |
Why?
| | Cloning, Molecular | 2 | 2000 | 538 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2001 | 36 | 0.040 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2001 | 20 | 0.040 |
Why?
| | Exons | 3 | 2015 | 364 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2001 | 54 | 0.040 |
Why?
| | Visual Cortex | 1 | 2002 | 84 | 0.040 |
Why?
| | Binding, Competitive | 1 | 2001 | 185 | 0.040 |
Why?
| | Movement | 1 | 2004 | 293 | 0.040 |
Why?
| | Chromosome Aberrations | 2 | 1999 | 166 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2007 | 789 | 0.040 |
Why?
| | Hallucinations | 1 | 2001 | 32 | 0.040 |
Why?
| | Cell Count | 1 | 2001 | 319 | 0.040 |
Why?
| | Nutritional Requirements | 1 | 2021 | 78 | 0.040 |
Why?
| | Fornix, Brain | 1 | 2000 | 5 | 0.040 |
Why?
| | Family Health | 1 | 2001 | 191 | 0.040 |
Why?
| | Denervation | 1 | 2000 | 27 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 376 | 0.040 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2000 | 49 | 0.040 |
Why?
| | Point Mutation | 2 | 1999 | 241 | 0.040 |
Why?
| | Multifactorial Inheritance | 1 | 2001 | 209 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 896 | 0.040 |
Why?
| | Blotting, Western | 3 | 2005 | 1184 | 0.040 |
Why?
| | Blotting, Northern | 2 | 2005 | 203 | 0.040 |
Why?
| | Binding Sites | 1 | 2002 | 1311 | 0.040 |
Why?
| | Cocaine | 1 | 2001 | 162 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1851 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 979 | 0.040 |
Why?
| | Fathers | 1 | 1999 | 53 | 0.040 |
Why?
| | Genetic Testing | 1 | 2001 | 483 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1989 | 592 | 0.030 |
Why?
| | Cell Movement | 1 | 2002 | 963 | 0.030 |
Why?
| | Self Medication | 1 | 1998 | 12 | 0.030 |
Why?
| | Developmental Disabilities | 1 | 2021 | 281 | 0.030 |
Why?
| | Cholinergic Agents | 1 | 1998 | 18 | 0.030 |
Why?
| | Genetics, Population | 1 | 1999 | 217 | 0.030 |
Why?
| | Electric Conductivity | 2 | 1998 | 85 | 0.030 |
Why?
| | Heterozygote | 1 | 1998 | 314 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2001 | 1723 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1998 | 148 | 0.030 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1997 | 5 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2000 | 574 | 0.030 |
Why?
| | Conditioning, Classical | 2 | 2008 | 119 | 0.030 |
Why?
| | Base Sequence | 3 | 2009 | 2171 | 0.030 |
Why?
| | Parents | 2 | 2015 | 1407 | 0.030 |
Why?
| | Age Factors | 2 | 2006 | 3346 | 0.030 |
Why?
| | Memory Disorders | 1 | 1998 | 197 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2013 | 318 | 0.030 |
Why?
| | Sensory Thresholds | 1 | 1996 | 31 | 0.030 |
Why?
| | Motor Activity | 2 | 1992 | 718 | 0.030 |
Why?
| | Nerve Fibers | 1 | 1995 | 105 | 0.030 |
Why?
| | Receptors, Glutamate | 1 | 1995 | 26 | 0.030 |
Why?
| | Nerve Growth Factors | 1 | 1995 | 79 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 196 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 331 | 0.030 |
Why?
| | Placenta | 1 | 2021 | 787 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2007 | 6085 | 0.030 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 1994 | 14 | 0.030 |
Why?
| | Cholinergic Fibers | 1 | 1993 | 19 | 0.020 |
Why?
| | Aging | 2 | 1999 | 1973 | 0.020 |
Why?
| | Genetic Engineering | 1 | 1994 | 88 | 0.020 |
Why?
| | Horseradish Peroxidase | 1 | 1993 | 26 | 0.020 |
Why?
| | Orientation | 1 | 1994 | 50 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 1995 | 1043 | 0.020 |
Why?
| | Neuromuscular Junction | 1 | 1994 | 65 | 0.020 |
Why?
| | Synaptic Vesicles | 1 | 1993 | 40 | 0.020 |
Why?
| | Axonal Transport | 1 | 1993 | 26 | 0.020 |
Why?
| | Chronic Disease | 1 | 1999 | 1812 | 0.020 |
Why?
| | Temporal Lobe | 1 | 1993 | 107 | 0.020 |
Why?
| | Habituation, Psychophysiologic | 1 | 1993 | 57 | 0.020 |
Why?
| | Tissue Banks | 1 | 2013 | 17 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2013 | 45 | 0.020 |
Why?
| | DNA Probes | 1 | 2013 | 59 | 0.020 |
Why?
| | Nomifensine | 1 | 1992 | 2 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 2013 | 52 | 0.020 |
Why?
| | Poly A | 1 | 1993 | 50 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2013 | 1777 | 0.020 |
Why?
| | Genes, MHC Class I | 1 | 2013 | 37 | 0.020 |
Why?
| | Receptors, sigma | 1 | 1992 | 3 | 0.020 |
Why?
| | Sympathomimetics | 1 | 1992 | 19 | 0.020 |
Why?
| | Peptides | 1 | 1999 | 999 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1992 | 71 | 0.020 |
Why?
| | Biogenic Monoamines | 1 | 1992 | 17 | 0.020 |
Why?
| | Benzylamines | 1 | 1992 | 44 | 0.020 |
Why?
| | Tubocurarine | 1 | 1992 | 6 | 0.020 |
Why?
| | Muscles | 1 | 1994 | 330 | 0.020 |
Why?
| | Mecamylamine | 1 | 1992 | 6 | 0.020 |
Why?
| | Levodopa | 1 | 1992 | 40 | 0.020 |
Why?
| | N-Methylaspartate | 1 | 1992 | 43 | 0.020 |
Why?
| | Parasympatholytics | 1 | 1992 | 11 | 0.020 |
Why?
| | Injections, Intraventricular | 1 | 1992 | 59 | 0.020 |
Why?
| | Microelectrodes | 1 | 1992 | 49 | 0.020 |
Why?
| | Nervous System | 1 | 1992 | 69 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2012 | 21 | 0.020 |
Why?
| | Temperature | 1 | 1995 | 633 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 337 | 0.020 |
Why?
| | Genotyping Techniques | 1 | 2012 | 71 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2002 | 8347 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 1997 | 1454 | 0.020 |
Why?
| | DNA Replication | 1 | 1993 | 249 | 0.020 |
Why?
| | RNA | 2 | 2013 | 912 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1368 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 2003 | 2883 | 0.020 |
Why?
| | Introns | 2 | 2003 | 256 | 0.020 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1994 | 414 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 452 | 0.020 |
Why?
| | Adenylate Cyclase Toxin | 1 | 1989 | 6 | 0.020 |
Why?
| | Virulence Factors, Bordetella | 1 | 1989 | 15 | 0.020 |
Why?
| | Pertussis Toxin | 1 | 1989 | 24 | 0.020 |
Why?
| | Risk Assessment | 1 | 1999 | 3752 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 1989 | 19 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 1994 | 574 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2009 | 85 | 0.020 |
Why?
| | Autoanalysis | 1 | 1989 | 8 | 0.020 |
Why?
| | Adenylyl Cyclases | 1 | 1989 | 60 | 0.020 |
Why?
| | Electrochemistry | 1 | 1989 | 70 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1083 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2823 | 0.020 |
Why?
| | Yohimbine | 1 | 1988 | 11 | 0.020 |
Why?
| | Dioxins | 1 | 1988 | 7 | 0.020 |
Why?
| | GTP-Binding Proteins | 1 | 1989 | 153 | 0.020 |
Why?
| | Dioxanes | 1 | 1988 | 11 | 0.020 |
Why?
| | Receptors, Adrenergic | 1 | 1988 | 20 | 0.020 |
Why?
| | Gene Dosage | 1 | 2009 | 145 | 0.020 |
Why?
| | Tyramine | 1 | 1988 | 8 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2009 | 328 | 0.020 |
Why?
| | Pulse | 1 | 1988 | 29 | 0.020 |
Why?
| | Tobacco Use Disorder | 1 | 2010 | 217 | 0.020 |
Why?
| | Fluphenazine | 1 | 1987 | 4 | 0.020 |
Why?
| | Saliva | 1 | 1989 | 249 | 0.020 |
Why?
| | Audiometry, Evoked Response | 1 | 1987 | 15 | 0.020 |
Why?
| | Stereoisomerism | 1 | 1987 | 103 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 428 | 0.020 |
Why?
| | Autoradiography | 2 | 1997 | 66 | 0.020 |
Why?
| | Tyrosine | 1 | 1988 | 217 | 0.020 |
Why?
| | Mutation | 2 | 2015 | 4090 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 198 | 0.010 |
Why?
| | alpha Catenin | 1 | 2005 | 11 | 0.010 |
Why?
| | Transcription Factors | 1 | 1994 | 1736 | 0.010 |
Why?
| | ROC Curve | 1 | 2007 | 618 | 0.010 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 50 | 0.010 |
Why?
| | Microarray Analysis | 1 | 2005 | 117 | 0.010 |
Why?
| | Suicide | 1 | 1993 | 729 | 0.010 |
Why?
| | Patient Selection | 1 | 2009 | 739 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 532 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 1987 | 286 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1512 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2002 | 42 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2009 | 1430 | 0.010 |
Why?
| | Artifacts | 1 | 2002 | 143 | 0.010 |
Why?
| | Sex Factors | 1 | 2006 | 2110 | 0.010 |
Why?
| | Diet | 1 | 1988 | 1278 | 0.010 |
Why?
| | Contig Mapping | 1 | 1998 | 9 | 0.010 |
Why?
| | Genes, Duplicate | 1 | 1998 | 4 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1998 | 81 | 0.010 |
Why?
| | Receptors, Presynaptic | 1 | 1998 | 10 | 0.010 |
Why?
| | Models, Biological | 1 | 2005 | 1764 | 0.010 |
Why?
| | Macaca radiata | 1 | 1997 | 15 | 0.010 |
Why?
| | Autopsy | 1 | 1997 | 94 | 0.010 |
Why?
| | Organ Specificity | 1 | 1997 | 309 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 1996 | 396 | 0.010 |
Why?
| | Species Specificity | 1 | 1996 | 546 | 0.010 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 1995 | 42 | 0.010 |
Why?
| | Gene Amplification | 1 | 1995 | 118 | 0.010 |
Why?
| | Isomerases | 1 | 1994 | 7 | 0.010 |
Why?
| | Protein Disulfide-Isomerases | 1 | 1994 | 12 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1994 | 55 | 0.010 |
Why?
| | DNA Primers | 1 | 1995 | 505 | 0.010 |
Why?
| | tau Proteins | 1 | 1995 | 105 | 0.010 |
Why?
| | Endopeptidases | 1 | 1994 | 80 | 0.010 |
Why?
| | Molecular Biology | 1 | 1994 | 58 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 311 | 0.010 |
Why?
| | Glycosylation | 1 | 1994 | 173 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1994 | 143 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1994 | 335 | 0.010 |
Why?
| | DNA | 1 | 1998 | 1437 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2131 | 0.000 |
Why?
| | Idazoxan | 1 | 1988 | 1 | 0.000 |
Why?
| | Phentolamine | 1 | 1988 | 19 | 0.000 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1988 | 19 | 0.000 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1988 | 58 | 0.000 |
Why?
| | Rats, Inbred F344 | 1 | 1988 | 268 | 0.000 |
Why?
| | Desipramine | 1 | 1988 | 10 | 0.000 |
Why?
| | Magnesium | 1 | 1987 | 157 | 0.000 |
Why?
| | DNA-Binding Proteins | 1 | 1994 | 1482 | 0.000 |
Why?
|
|
Freedman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|